hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo’ Khan talked with Proactive's Stephen Gunnion about the company’s latest contract win—a human challenge trial deal with Inhalon Pharma for an RSV antiviral.
Khan explained that the study, set to begin in the second half of 2026, will assess Inhalon’s mucosal RSV antiviral. The drug, delivered via inhalation, is designed to trap the virus on the mucosal lining, preventing it from reaching the lungs. He noted the broader implications of this technology, which could extend to other viruses such as influenza and coronaviruses.
Despite speculation that RSV research might slow down following vaccine approvals, Khan emphasised that the need for antiviral treatments remains. He highlighted that hVIVO has continued to expand its RSV challenge models and recently signed multiple contracts, reinforcing its position in this market.
Discussing broader trends, Khan noted that the challenge trial market remains strong despite previous slowdowns. He attributed recent delays to a single contract issue but confirmed that the company has seen an uptick in new signings. He also provided an update on the integration of CRS following its acquisition, stating that the transition is progressing well.
For more insights from industry leaders, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications!
#hVIVO #RSV #Biotech #ClinicalTrials #Pharma #InhalonPharma #MoKhan #Healthcare #DrugDevelopment #Investing #Stocks